Sheng‐Hua Chu

655 total citations
29 papers, 508 citations indexed

About

Sheng‐Hua Chu is a scholar working on Molecular Biology, Genetics and Hepatology. According to data from OpenAlex, Sheng‐Hua Chu has authored 29 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Genetics and 6 papers in Hepatology. Recurrent topics in Sheng‐Hua Chu's work include Glioma Diagnosis and Treatment (9 papers), Liver physiology and pathology (6 papers) and Epigenetics and DNA Methylation (6 papers). Sheng‐Hua Chu is often cited by papers focused on Glioma Diagnosis and Treatment (9 papers), Liver physiology and pathology (6 papers) and Epigenetics and DNA Methylation (6 papers). Sheng‐Hua Chu collaborates with scholars based in China. Sheng‐Hua Chu's co-authors include Yan‐Bin Ma, Dong‐Fu Feng, Pucha Jiang, Zhiqiang Li, Zhiqiang Li, Biao Yang, Zhiqiang Li, Jianhua Qiu, Hong Zhang and Hong Zhang and has published in prestigious journals such as SHILAP Revista de lepidopterología, BioMed Research International and International Journal of Nanomedicine.

In The Last Decade

Sheng‐Hua Chu

29 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sheng‐Hua Chu China 15 316 136 84 67 59 29 508
Haibin Wu China 13 249 0.8× 101 0.7× 145 1.7× 57 0.9× 56 0.9× 32 513
Chunhui Zhou China 10 294 0.9× 176 1.3× 158 1.9× 31 0.5× 67 1.1× 29 564
Kazuhiro Takara Japan 11 390 1.2× 106 0.8× 99 1.2× 27 0.4× 68 1.2× 16 573
Veronica De Gregorio Italy 9 174 0.6× 115 0.8× 183 2.2× 83 1.2× 59 1.0× 16 439
Bhopal Mohapatra United States 14 438 1.4× 79 0.6× 174 2.1× 69 1.0× 58 1.0× 34 691
Abdullah Alajati Germany 10 366 1.2× 114 0.8× 168 2.0× 49 0.7× 117 2.0× 17 595
Xiangwei Meng China 15 188 0.6× 83 0.6× 127 1.5× 44 0.7× 20 0.3× 38 435
Junjeong Choi South Korea 14 269 0.9× 174 1.3× 180 2.1× 176 2.6× 101 1.7× 19 602
А. Yu. Lupatov Russia 12 149 0.5× 53 0.4× 120 1.4× 138 2.1× 47 0.8× 57 427
Hirofumi Toi Japan 8 215 0.7× 73 0.5× 91 1.1× 14 0.2× 35 0.6× 17 372

Countries citing papers authored by Sheng‐Hua Chu

Since Specialization
Citations

This map shows the geographic impact of Sheng‐Hua Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng‐Hua Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng‐Hua Chu more than expected).

Fields of papers citing papers by Sheng‐Hua Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng‐Hua Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng‐Hua Chu. The network helps show where Sheng‐Hua Chu may publish in the future.

Co-authorship network of co-authors of Sheng‐Hua Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng‐Hua Chu. A scholar is included among the top collaborators of Sheng‐Hua Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng‐Hua Chu. Sheng‐Hua Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Biao, Yuan‐Bo Pan, Yan‐Bin Ma, & Sheng‐Hua Chu. (2020). Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas. Frontiers in Oncology. 10. 250–250. 8 indexed citations
2.
Chu, Sheng‐Hua & Yan‐Bin Ma. (2020). Evaluation of combination gene therapy with SLC22A18 upregulation and sequence binding protein 1 downregulation for glioma U251 cells in vitro and in vivo. SHILAP Revista de lepidopterología. 3(1). 16–16. 1 indexed citations
3.
Yang, Biao, et al.. (2020). Integrated Transcriptomic Analysis Reveals the Molecular Mechanism of Meningiomas by Weighted Gene Coexpression Network Analysis. BioMed Research International. 2020(1). 4927547–4927547. 1 indexed citations
4.
5.
Xu, Chengshi, Xinghuan Wang, Liming Dai, et al.. (2014). Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy. Journal of Translational Medicine. 12(1). 148–148. 16 indexed citations
6.
Chu, Sheng‐Hua, et al.. (2013). Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1. Molecular Biology Reports. 41(2). 977–986. 17 indexed citations
7.
Chu, Sheng‐Hua, Yan‐Bin Ma, Dong‐Fu Feng, Zhiqiang Li, & Pucha Jiang. (2013). Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy. Journal of Translational Medicine. 11(1). 69–69. 10 indexed citations
8.
Chu, Sheng‐Hua, Yan‐Bin Ma, Dong‐Fu Feng, et al.. (2012). Upregulation of SATB1 is associated with the development and progression of glioma. Journal of Translational Medicine. 10(1). 149–149. 46 indexed citations
9.
Chu, Sheng‐Hua, Yan‐Bin Ma, Dong‐Fu Feng, Zhiqiang Li, & Pucha Jiang. (2012). Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme. Molecular Medicine Reports. 7(1). 139–143. 19 indexed citations
10.
Chu, Sheng‐Hua, Dong‐Fu Feng, Yan‐Bin Ma, & Zhiqiang Li. (2012). Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo. International Journal of Nanomedicine. 7. 3659–3659. 63 indexed citations
11.
Chu, Sheng‐Hua, et al.. (2011). Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU. Oncology Letters. 2(6). 1139–1142. 12 indexed citations
12.
Chu, Sheng‐Hua. (2011). Expression of HGF and VEGF in the cerebral tissue of adult rats with chronic hydrocephalus after subarachnoid hemorrhage. Molecular Medicine Reports. 4(5). 785–91. 17 indexed citations
13.
Chu, Sheng‐Hua, Yan‐Bin Ma, Dong‐Fu Feng, et al.. (2011). Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. Journal of Clinical Neuroscience. 19(1). 95–98. 35 indexed citations
14.
Chu, Sheng‐Hua, Dong‐Fu Feng, Xueyuan Li, et al.. (2009). c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. Journal of Neuro-Oncology. 93(2). 183–189. 29 indexed citations
15.
Chu, Sheng‐Hua, et al.. (2009). Giant intradiploic epidermoid cyst of the occipital bone. Journal of Clinical Neuroscience. 16(11). 1478–1480. 18 indexed citations
16.
Chu, Sheng‐Hua, et al.. (2008). Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1. Molecular Biology Reports. 36(7). 1967–1975. 31 indexed citations
17.
Chu, Sheng‐Hua, et al.. (2007). c-Met Antisense Oligodeoxynucleotides as a Novel Therapeutic Agent for Glioma: In Vitro and In Vivo Studies of Uptake, Effects, and Toxicity. Journal of Surgical Research. 141(2). 284–288. 9 indexed citations
18.
Chu, Sheng‐Hua, et al.. (2006). C-Met antisense oligodeoxynucleotide inhibits growth of glioma cells. Surgical Neurology. 65(6). 533–538. 16 indexed citations
19.
Chu, Sheng‐Hua. (2005). Expression of hepatocyte growth factor and its receptor mRNA in brain astrocytomas. Tumori. 4 indexed citations
20.
Chu, Sheng‐Hua, et al.. (2005). [The expression of hepatocyte growth factor and its receptor in brain astrocytomas].. PubMed. 85(12). 835–8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haibin Wu Breakdown of academic impact, for papers by Chunhui Zhou Breakdown of academic impact, for papers by Kazuhiro Takara Breakdown of academic impact, for papers by Veronica De Gregorio Breakdown of academic impact, for papers by Bhopal Mohapatra Breakdown of academic impact, for papers by Abdullah Alajati Breakdown of academic impact, for papers by Xiangwei Meng Breakdown of academic impact, for papers by Junjeong Choi Breakdown of academic impact, for papers by А. Yu. Lupatov Breakdown of academic impact, for papers by Hirofumi Toi
Rankless by CCL
2026